Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Fig. 2

Cycle-based analysis (n = 497): (A) association of absolute change in hemoglobin, white blood cells (WBC) and platelets after each treatment cycle with cycle activity, linear trendline, (B) association of toxicity grade after each treatment cycle and cumulative treatment activity, (C) Sankey diagrams for change in CTC grade after each treatment cycle

Back to article page